Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 14/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.66 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168267 | 1.00 | GRIA2 (0.68) | GRIA2KCNH2KDM1AALDH1A1LMNA | |
| SCHEMBL4168262 | 1.00 | GRIA2 (0.68) | GRIA2KCNH2KDM1AALDH1A1LMNA | |
| SCHEMBL4097619 | 0.81 | GRIA2 (1.00) | GRIA2KCNH2KDM1A | |
| SCHEMBL4097616 | 0.81 | GRIA2 (1.00) | GRIA2KCNH2KDM1A | |
| SCHEMBL4097607 | 0.81 | GRIA2 (1.00) | GRIA2KCNH2KDM1A | |
| SCHEMBL4168112 | 0.80 | GRIA2 (0.48) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4168115 | 0.80 | GRIA2 (0.48) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4168109 | 0.80 | GRIA2 (0.48) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4958828 | 0.79 | GRIA2 (1.00) | GRIA2KCNH2 | |
| SCHEMBL2187890 | 0.78 | GRIA4 (0.55) | GRIA2KCNH2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | disclosed |
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | disclosed |
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GRIN1, GRM1, GRIN2C | GRIA2 16/4885KCNH2 1455/4885KDM1A 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.